Pharmacy & Therapeutics/Drug Utilization Review Committee

January 16, 2026
8:00 AM-2:00 PM

In person Option:
5700 Pasadena Ave NE,
Conference Room A
Albuquerque, NM 87113

Virtual option:
Microsoft Teams Need help?
Join the meeting now
Meeting ID: 226 278 712 907 01
Passcode: Fu75Gc2m

Dial in by phone
+1 505-312-4308,,680852743# United States, Albuquerque
(888) 506-1357,,680852743# United States (Toll-free)
Find a local number
Phone conference ID: 680 852 743#
For organizers: Meeting options | Reset dial-in PIN

Agenda Item	Leader
Introductions	K. Ryan
Approval of Agenda (Attachment A)	K. Ryan
State Updates • NM FFS/MCO Client Counts and Pharmacy	Conduent/K. Ryan

• Member Demographics	
RetroDUR	Conduent
Recent interventions • Polypharmacy with Psychotropic Medications (FY25 Q4)	Conduent
Summary reports • Underutilization of Statins in Diabetes Mellitus (FY25 Q3) (Attachment B)	Conduent
Data Results • SMART (FY24 Q4)	Conduent
Quarterly reports • Metabolic Monitoring of SGAs in Youth (Attachment C) • Opioid and SMR Overlap Report (Attachment D) • Opioid and Gabapentinoids Overlap Report (Attachment D) • Opioid and Benzodiazepine Overlap Report (Attachment D) • Opioid and Antipsychotic Overlap Report (Attachment D) • Opioid, Antipsychotics, and Benzodiazepines Overlap Report (Attachment D) • Opioid and Non-BZD Sedatives Overlap Report (Attachment D) • Opioid-Stimulants Overlap Report (Attachment D)	Conduent
Upcoming Interventions • Opioid Newsletter (FY26 Q1) (Attachment E)	Conduent
Break	
Closed Session PDL Class Review	K. Ryan
Open Session	K. Ryan
HCA Administrative Updates • P&T Member from BAC • CMMI Models • Autoimmune definition	Prime/ K. Ryan
Drug Class Review • Antipsychotics • Cytokine and CAM Antagonist • Hepatitis C Agents • HIV/AIDS • Opiate Dependance Treatments • Drug Classes Appendix A (Time permitting) ○ Acne Agents, Topical	Prime

○ Alzheimer's Agents ○ Analgesics, Narcotics Short ○ Analgesics, Narcotics Long ○ Angiotensin Modulators ○ Angiotensin Modulator Combination ○ Antibiotic, GI ○ Antibiotics, Topical ○ Antibiotics, Vaginal ○ Anticoagulants ○ Antidepressants, Other* ○ Antidepressants, SSRI* ○ Antifungal, Oral ○ Antifungal, Topical ○ Antihistamines, Minimally Sedating ○ Antihypertensives, Sympatholytic ○ Antihyperuricemics ○ Antiparasitics, Topical ○ Antipsoriatics, Topical* ○ Antivirals, General ○ Anxiolytics ○ Beta-Blockers ○ Bladder Relaxants ○ BPH Treatments ○ Bronchodilators, Beta Agonist ○ Calcium Channel Blockers ○ Cephalosporins and Related Antibiotics ○ Diuretics ○ Epinephrine, Self Injected ○ Fluoroquinolones, Oral ○ Glucagon Agents ○ Hepatitis B Agents ○ Histamine II Receptors Blockers ○ Hypoglycemics, Alpha-glucosidase Inhibitors ○ Hypoglycemics, Meglitnides ○ Hypoglycemics, Meformins ○ Hypoglycemics, Sulfonylureas ○ Hypoglycemics, TZD ○ Intranasal Rhinitis Agents ○ Leukotriene Modifiers ○ Lipotropics, Statins ○ Macolides/Ketolides ○ Antibiotics Uncomplicated UTI ○ NSAIDS ○ Ophthalmic Antibiotics ○ Ophthalmic Antibiotics-Steroid Combinations ○ Ophthalmic for Allergic Conjunctivitis	

○ Ophthalmic, Anti-inflammatories ○ Ophthalmic, Glaucoma Agents ○ Opiate Dependence Treatments ○ Otic Antibiotics ○ Pancreatic Enzymes ○ Phosphate Binders ○ Platelet Aggregation Inhibitors ○ Potassium Binders ○ Prenatal Vitamins ○ Proton Pump Inhibitors ○ Skeletal Muscle Relaxants ○ Smoking Cessation ○ Steroids, Topical Very High ○ Steroids, Topical High ○ Steroids, Topical Medium ○ Steroids, Topical low ○ Tetracyclines ○ Thyroid Hormones ○ Ulcerative Colitis Agents ○ Uterine Disorder Treatments ○ Vasodilators, Coronary	
Open Comment	K. Ryan
Adjournment	K. Ryan